Index -
P/E -
EPS (ttm) -1.10
Insider Own 14.23%
Shs Outstand 16.77M
Perf Week 15.89%
Market Cap 15.12M
Forward P/E -
EPS next Y -1.43
Insider Trans 0.00%
Shs Float 14.49M
Perf Month -51.62%
Income -16.44M
PEG -
EPS next Q -0.17
Inst Own 7.39%
Short Float 3.20%
Perf Quarter -56.13%
Sales 0.00M
P/S -
EPS this Y 26.96%
Inst Trans 2.14%
Short Ratio 3.93
Perf Half Y -63.91%
Book/sh 0.16
P/B 5.63
EPS next Y -70.24%
ROA -250.15%
Short Interest 0.46M
Perf Year -73.20%
Cash/sh 0.34
P/C 2.62
EPS next 5Y -
ROE -498.16%
52W Range 0.72 - 5.28
Perf YTD -76.63%
Dividend Est. -
P/FCF -
EPS past 5Y -17.77%
ROI -616.96%
52W High -83.05%
Beta -1.85
Dividend TTM -
Quick Ratio 1.80
Sales past 5Y 0.00%
Gross Margin -
52W Low 24.31%
ATR (14) 0.14
Dividend Ex-Date -
Current Ratio 1.80
EPS Y/Y TTM -4.10%
Oper. Margin -
RSI (14) 28.90
Volatility 14.48% 15.38%
Employees 4
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 11.00
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 28.02%
Payout -
Rel Volume 0.53
Prev Close 0.88
Sales Surprise -
EPS Surprise -17.24%
Sales Q/Q -
Earnings Nov 13 BMO
Avg Volume 118.08K
Price 0.89
SMA20 -24.38%
SMA50 -45.61%
SMA200 -56.83%
Trades
Volume 13,245
Change 1.40%
Dec-11-24 11:00AM
Dec-09-24 08:00AM
Nov-28-24 09:55AM
Nov-27-24 07:00AM
Nov-22-24 12:25PM
04:21PM
Loading…
Nov-21-24 04:21PM
Nov-20-24 07:01AM
Nov-18-24 07:00AM
Nov-14-24 02:07AM
Nov-13-24 07:00AM
Oct-31-24 03:00PM
Oct-28-24 10:00AM
Oct-21-24 07:00AM
Oct-17-24 08:00AM
Oct-16-24 08:00AM
01:00PM
Loading…
Oct-14-24 01:00PM
Oct-11-24 11:05AM
10:50AM
Sep-26-24 07:00AM
Sep-24-24 07:00AM
Sep-09-24 08:30AM
Aug-26-24 09:15AM
07:00AM
Aug-19-24 09:20AM
Aug-10-24 08:18AM
Aug-09-24 09:30AM
07:01AM
Jul-17-24 07:00AM
Jul-16-24 07:00AM
Jul-15-24 07:00AM
09:30AM
Loading…
Jun-06-24 09:30AM
May-16-24 03:00AM
May-15-24 10:40PM
(Thomson Reuters StreetEvents) +7.66%
09:53AM
09:00AM
07:00AM
May-02-24 07:00AM
Apr-25-24 10:12AM
Apr-23-24 10:57AM
Mar-21-24 03:01AM
Mar-19-24 09:32AM
Mar-18-24 10:01PM
(Thomson Reuters StreetEvents)
09:52AM
07:01AM
Mar-04-24 07:01AM
Feb-27-24 07:01AM
Feb-23-24 09:30AM
Feb-16-24 09:30AM
Feb-02-24 09:30AM
Feb-01-24 09:33AM
Jan-29-24 07:00AM
Jan-26-24 10:55AM
Jan-23-24 07:01AM
Jan-19-24 09:30AM
Jan-17-24 01:26PM
07:01AM
Jan-05-24 09:30AM
Jan-03-24 08:00AM
Dec-11-23 07:01AM
Dec-08-23 09:46AM
Dec-07-23 09:20AM
Dec-01-23 09:30AM
Nov-24-23 09:30AM
Nov-17-23 09:30AM
Nov-15-23 02:35PM
Nov-14-23 07:01AM
Nov-09-23 08:52AM
Nov-02-23 07:01AM
Oct-25-23 07:01AM
Oct-20-23 10:43AM
Oct-19-23 07:01AM
Oct-02-23 07:01AM
Sep-12-23 07:01AM
Aug-22-23 07:01AM
Aug-14-23 07:01AM
Jul-24-23 07:01AM
Jul-11-23 07:00AM
Jul-07-23 09:30AM
Jun-30-23 09:35AM
Jun-20-23 07:01AM
Jun-15-23 07:01AM
May-16-23 08:45AM
May-12-23 07:01AM
May-05-23 05:01PM
Apr-22-23 09:42AM
Apr-21-23 09:30AM
Apr-19-23 07:01AM
Apr-13-23 09:30AM
Apr-11-23 07:01AM
Mar-23-23 04:00PM
Mar-18-23 02:03AM
Mar-16-23 07:01AM
Mar-06-23 08:00AM
Feb-14-23 08:01AM
Feb-07-23 08:49AM
Jan-24-23 07:00AM
Jan-19-23 09:00AM
Jan-16-23 08:01AM
Dec-29-22 06:02AM
Dec-28-22 10:39AM
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Sailer Carl Director Jan 19 '24 Option Exercise 3.55 19,737 70,066 112,552 Jan 22 06:15 AM DELUCCIA ROBERT J Director Jan 03 '24 Option Exercise 3.55 19,737 70,066 960,935 Jan 04 04:26 PM LUCI DAVID P President and CEO Jan 03 '24 Option Exercise 3.55 19,737 70,066 1,048,197 Jan 04 04:24 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite